Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Atomo Diagnostics Ltd. ( (AU:AT1) ) has issued an announcement.
Atomo Diagnostics Limited has issued 36,259,457 fully paid ordinary shares to new and existing investors, including a Director, at an issue price of $0.0185 per share, as part of a previously announced plan. Additionally, the company issued 14,723,685 shares under a Share Purchase Plan. This move is part of Atomo’s strategy to strengthen its financial position and support its operations in the competitive diagnostic market, potentially impacting its market positioning and stakeholder interests.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian-headquartered medical device company that supplies unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The company’s patented devices are designed to simplify testing procedures, enhance usability, and improve reliability for rapid point-of-care and at-home testing applications. Atomo has commercialized several products internationally and has supply agreements for testing applications targeting infectious diseases such as COVID-19, HIV, viral vs bacterial differentiation, and female health.
Average Trading Volume: 610,084
Technical Sentiment Signal: Sell
Current Market Cap: A$10.29M
See more insights into AT1 stock on TipRanks’ Stock Analysis page.